- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Flat panel list prices fall
Planar Systems cut list prices last month for its medical-grade flat-panel monitors by almost half, framing the move as part of an effort to make flat-panel display systems more affordable. The company's most popular product, a 3-megapixel dual-display
Planar Systems cut list prices last month for its medical-grade flat-panel monitors by almost half, framing the move as part of an effort to make flat-panel display systems more affordable. The company's most popular product, a 3-megapixel dual-display monitor, which was listed for $28,000 now lists for $15,000. Planar has maintained margins on its products by taking costs out of their manufacture. This was achieved by redesigning boards and outsourcing manufacturing to Asia, according to the company.
Planar executives said the price cuts should allow a wider range of healthcare facilities to deploy Planar displays. They noted, however, that the new prices on Planar's 2-, 3-, and 5- megapixel monitors bring the company more in line with competitors whose products deliver similar image quality.
Planar's decision to reduce list prices marked an evolutionary step in the sales history of flat-panel monitors: the transition from an early-adopter market to one of mass sales, according to Quest International, which distributes flat-panel medical monitors made by Totoku of Japan. Sales will increasingly be decided by software and support services, Planar and Quest executives agreed.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
